IBM Research Arm To Invest $1 Billion In India Trials, Drug-Safety Testing (India)
This article was originally published in PharmAsia News
IBM T J Watson, the research arm of U.S. giant IBM, plans to invest up to $1 billion into pharmaceutical and health services in India, its manager says. In the drug-making area, up to 40 percent of the total investment is to be spent on clinical trials and contracting research space in India. Part of another 30 percent may go for technology to detect spurious drugs, J. Sairamesh said, noting Ranbaxy's recent U.S. recall of 73 million doses of its painkiller Gabapentin (gabapentin). (Click here for more
You may also be interested in...
Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.